

Changes to the Preferred Drug List (PDL), June 2007

The Department announces the following changes to the Preferred Drug List dated 1/1/2007 and last previously modified 2/9/2007. The changes will take place as close to June 1 as feasible.

Sedative Hypnotic Non-Barbiturates

Add generic zolpidem without prior authorization

There will **not** be a reclassification of the category as recommended in March

Angiotensin Receptor Antagonists

Remove prior authorization from Micardis and Micardis HCT

Add prior authorization to Atacand and Atacand HCT

Calcium Channel Blockers-Dihydropyridine

Add amlodipine without prior authorization

Add prior authorization to Norvasc

Lipotropics-Statins

Add prior authorization to Altoprev®

Remove prior authorization from pravastatin

Remove prior authorization from Crestor®.

Nasal Steroids

Remove prior authorization from Flonase

Add prior authorization to fluticasone propionate

Inhaled Anticholinergics

Add Atrovent and Atrovent HFA without prior authorization

Ophthalmic Antihistamines

Add prior authorization to ketotifen

Beta Adrenergic-Short Acting

Add Ventolin HFA without prior authorization

Add prior authorization to Xopenex HFA

Add Proair HFA and Proventil HFA with prior authorization

Create the following new PDL classes:

Low Molecular Weight Heparins:

Add Arixtra, Fragmin and Lovenox without prior authorization

Add Innohep with prior authorization

Hematopoietic Agents

Add Aranesp, Epogen, Procrit without prior authorization (Clinical PA remains)

Combination Benzoyl peroxide + clindamycin

Add Benzaclin without prior authorization

Add Duac with prior authorization